MalariaDiag
Biotechnology & Life Sciences (Research, Medical Devices) | Cameroon
38.1%
Early-Stage / High Risk
Ideation or early seed stage. The business model is unvalidated, the team is incomplete, or traction is non-existent.
Action: The company is not ready for deployment. Recommendation: Orientation towards local incubation or basic training programs.
Axis 1: Market & Economic Model
Market Readiness (Commercial Dev.)
35.0%
⚠️ Risk: Adoption risk. The product has not found its Product-Market Fit. The acquisition strategy is vague, and the customer base is almost non-existent.
Business Model
30.0%
⚠️ Risk: Viability risk. Model based on one-off revenues or custom services (very low scalability). High dependence on suppliers or partners.
International
20.0%
⚠️ Risk: Strictly domestic focus. Export capacities or integration into regional value chains are non-existent.
Axis 2: Product & Innovation
Technology Readiness (R&D / Innovation)
65.0%
⚡ Structuring: Functional product with proven technological differentiation but replicable in the medium term. Partial IP protection (e.g., domestic only).
Axis 3: Execution Capabilities (Operations & HR)
Organization and Operations
35.0%
⚠️ Risk: High operational risk. Everything relies on the founders. Non-existent support functions and undocumented processes. Cannot absorb growth.
Human Capital
40.0%
⚠️ Risk: Major skills imbalance (e.g., 100% technical team without sales profile). High turnover and difficulty retaining talent.
Leadership (Leaders)
50.0%
⚡ Structuring: Committed and aligned leadership team, but may lack complementarity or prior experience in accelerated growth (Scale).
Axis 4: Financial Health
Financing
30.0%
⚠️ Risk: Red zone. High cash-burn, uncontrolled working capital requirement (WCR), less than 6 months of available cash.